Kennedy Ferruggia, Assistant Editor

Approximately 61% of individuals said respiratory syncytial virus (RSV vaccination for adults 60 years and older is effective.

If approved, the combination of avutometinib with defactinib could be the first FDA-approved treatment option for low-grade serous ovarian cancer.

The inaccurate claim that these products pose a heavy metal risk is potentially detrimental, as it could discourage pregnant women from using vital prenatal supplements.

Immunocompromised older adults developed fewer antibodies against RSV following vaccination compared with immunocompetent individuals.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

Short-term spinal cord stimulation could provide long-term pain relief and improve the overall quality of life for individuals with herpes zoster-associated pain and postherpetic neuralgia.

VGT-1849A could reduce JAK2 activity, lessening the disease burden faced by individuals with PV while providing a favorable safety profile.

Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.

Clesrovimab would be the first and only single dose immunization indicated for infants regardless of weight, aimed to protect against their first RSV season.

The findings suggest that VZV is a common cause of CNS infections, even when there is no visible rash.

Pharmacists and health care providers can recommend healthy foods that are rich in choline and iodine if individuals are not receiving enough in prenatal vitamin supplements.

Ustekinumab-stba (Steqeyma; Celltrion) is a subcutaneous treatment for adult and pediatric patients with plaque psoriasis arthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis.

Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.

Nemolizumab exclusively targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.

Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.

The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.

The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.

Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Komal Jhaveri MD, FACP, shares that the combination of imlunestrant plus abemaciclib further improved progression-free survival compared to imlunestrant alone.

Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.

Further research is needed to identify the influence of high-dose vitamin D supplementation among vitamin D–deficient populations.

Pharmacists play a key role in vaccination efforts to prevent respiratory illnesses.

Durvalumab could offer further treatment for individuals with muscle-invasive bladder cancer.

Reduced hospital masking and testing policies increased rates of hospital-onset respiratory infections, including RSV.

During a 15-year period, 1 in 5 older adults living with COPD received a shingles vaccine.

High-dose vitamin C, when combined with chemotherapy, has shown the potential to double the survival rate of patients with late-stage metastatic pancreatic cancer.